BeOne Medicines AG (ONC) Fair Value & Analysis
Healthcare · US · Market cap $28.0B
BeOne Medicines AG
ONC · US
Fair value as of: Jun 24, 2026
From 24 valuation models · updated 6 days ago
Fair value updated Jun 24, 2026 — revised from $140.47 to $114.29 (−18.6%) since Jun 23, 2026. Share price −1.0% over the past month.
Price vs Fair Value (12 months)
12‑month range $233.51 – $365.76 · fair‑value band $85.16 – $157.35 · the $276.13 price screens above the $114.29 fair value. As of Jun 24, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
BeOne Medicines AG (ONC) currently trades at $276.13, while our model-based Fair Value estimate is $114.29 — implying the stock looks roughly 58.6% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).
Over the trailing twelve months, BeOne Medicines AG generated revenue of $5.7B at a net margin of 8.9%. Revenue grew 35.5% year over year. It earns a return on equity of 12.4%. The balance sheet holds a net cash position of $2.5B. Fundamentals as of Jun 24, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 24, 2026. TTM = trailing twelve months.
About the company
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T18…
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
BeOne Medicines AG reported revenue of $5.3B in FY2025 versus $1.2B in FY2021, a compound +46.0%/yr. Reported net income was $287M in FY2025.
Open the full interactive analysis →
Recent news
- Kymera Appoints Felix Baker As Board Chairman, Succeeds Bruce Booth
- Here is Why BeOne (ONC) One of the Most Promising Long-Term Stocks to Buy According to Analysts
- BeOne Medicines (ONC): Citizens Sees an Inflection Point in Its Cancer Pipeline
- BeOne Medicines (ONC) Presents Updated BRUKINSA Phase 3 Data at EHA
External third-party headlines (Yahoo Finance, Reuters and others) — not an editorial selection, not financial advice.
Similar stocks
6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jun 24, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$607.20 | R$74.60 | -88% |
| Regeneron Pharmaceuticals, Inc REGN | $635.45 | $547.01 | -14% |
| UCB SA UCB | €251.70 | €180.06 | -28% |
| argenx SE ARGNF | $900.00 | $390.80 | -57% |
| Alnylam Pharmaceuticals, Inc ALNY | $291.22 | $111.44 | -62% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is BeOne Medicines AG (ONC) undervalued?
What is the fair value of ONC?
What is the quality score of ONC?
What is the revenue of BeOne Medicines AG (ONC)?
What is the net profit margin of ONC?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.